These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39294686)

  • 1. SNAI1: a key modulator of survival in lung squamous cell carcinoma and its association with metastasis.
    Li B; Li R
    J Cardiothorac Surg; 2024 Sep; 19(1):531. PubMed ID: 39294686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyroptosis-related long-noncoding RNA signature predicting survival and immunotherapy efficacy in patients with lung squamous cell carcinoma.
    Zhan X; Li J; Ding Y; Zhou F; Zeng R; Lei L; Zhang Y; Feng A; Qu Y; Yang Z
    Clin Exp Med; 2024 Jul; 24(1):145. PubMed ID: 38960987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of
    Lin H; Wang J; Shi Q; Wu M
    PeerJ; 2024; 12():e17338. PubMed ID: 38708353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of Synuclein-
    Yang J; Pan Y; Peng L; Zhang L; Zhao J; Zheng Z; Zheng J; Xu X; Zeng Y
    Biomed Res Int; 2022; 2022():6534626. PubMed ID: 35434126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
    Huang G; Zhang J; Gong L; Huang Y; Liu D
    BMC Cancer; 2021 May; 21(1):626. PubMed ID: 34044809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis-related genes.
    Diao X; Guo C; Liu L; Wang G; Li S
    Thorac Cancer; 2021 Dec; 12(23):3236-3247. PubMed ID: 34672420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
    Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
    BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nine-long non-coding RNA signature for prognosis prediction of patients with lung squamous cell carcinoma.
    Huang G; Huang Q; Xie Z; Zhou H; Cao J; Shi L; Yang M
    Cancer Biomark; 2019; 26(3):239-247. PubMed ID: 31524143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma.
    Ju Q; Zhao YJ; Ma S; Li XM; Zhang H; Zhang SQ; Yang YM; Yan SX
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1711-1723. PubMed ID: 32356177
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Yi C; Zang N; Gao L; Ren F
    Aging (Albany NY); 2024 May; 16(11):9498-9517. PubMed ID: 38819947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
    Gao X; Wu Y; Yu W; Li H
    Oncotarget; 2016 Dec; 7(49):81670-81679. PubMed ID: 27835574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
    Xu F; Zhang H; Chen J; Lin L; Chen Y
    Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the Role and Regulation Mechanism of hsa-miR-147b in Lung Squamous Cell Carcinoma Based on The Cancer Genome Atlas Database.
    Ke D; Guo Q; Fan TY; Xiao X
    Cancer Biother Radiopharm; 2021 Apr; 36(3):280-291. PubMed ID: 33112657
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of prognostic signature related with twelve types of programmed cell death in lung squamous cell carcinoma.
    Li S; Ding B; Weng D
    J Cardiothorac Surg; 2024 Oct; 19(1):569. PubMed ID: 39354528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
    Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
    Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
    Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
    Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.